Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Rhea-AI Summary
Allogene Therapeutics (NASDAQ: ALLO) will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
According to the company, the listen-only webcast will be available on its investor website, with a replay accessible for about 30 days. Registered participants who request to speak will receive a personal PIN.
Positive
- None.
Negative
- None.
News Market Reaction – ALLO
On the day this news was published, ALLO declined 4.68%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $31M from the company's valuation, bringing the market cap to $625M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALLO gained 1.83% while peers showed mixed moves: VNDA +4.7%, RAPT +0.07%, but CADL -5.23% and NMRA -0.29%, indicating only a modestly supportive sector backdrop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Neutral | -9.4% | Outlined participation in two Q1 2026 investor conferences. |
| Jan 08 | Pipeline outlook | Positive | +0.0% | Positioned 2026 as program-defining with multiple H1 2026 readouts. |
| Dec 15 | Legal arbitration win | Positive | +4.8% | Favorable ruling confirming cema-cel control and commercialization path. |
| Nov 10 | Conference participation | Neutral | +0.0% | Announced three late-2025 investor conference appearances. |
| Nov 06 | Earnings and update | Positive | +12.4% | Reported Q3 2025 financials and key clinical milestones timing. |
Historically, more substantive updates such as earnings and legal wins saw positive price alignment, while conference and program updates often produced flat or negative reactions.
In the last six months, Allogene has reported Q3 2025 earnings, highlighted 2026 as a program-defining year, secured a favorable arbitration outcome on cema-cel rights, and repeatedly announced conference participation. Notably, Q3 2025 results on Nov 06, 2025 and the arbitration news on Dec 15, 2025 coincided with positive moves, while conference and strategy updates sometimes saw limited or negative response. The newly announced Q4 and FY 2025 earnings date fits into this cadence of regular financial and pipeline communications.
Market Pulse Summary
This announcement sets the timing for Allogene’s Q4 and full-year 2025 results and a business update call on March 12, 2026. Investors will likely focus on cash runway, operating expenses, and progress on pivotal programs such as ALPHA3 and ALLO-329, given prior guidance. Context from recent arbitration outcomes, program milestones, and evolving ownership disclosures may also inform how the new financial and pipeline details are interpreted once released.
Key Terms
allogeneic car t medical
AI-generated analysis. Not financial advice.
- Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-Q filed for the quarter ended September 30, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When will Allogene Therapeutics (ALLO) release Q4 and full year 2025 results?
How can investors join Allogene Therapeutics (ALLO) conference call on March 12, 2026?
Where will the Allogene Therapeutics (ALLO) webcast be hosted and how long is replay available?
What time is Allogene Therapeutics (ALLO) live webcast and conference call on March 12, 2026?
Can shareholders ask questions during the Allogene Therapeutics (ALLO) March 12, 2026 call?
Will Allogene Therapeutics (ALLO) provide financial and business details in the March 12, 2026 presentation?
